Evidence map›Paper›PMID 31849976›Full record

ArticleFrontiers in immunology2019

Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic Keratoses.

Elizabeth S Borden, Paul Kang, Heini M Natri, Tanya N Phung, Melissa A Wilson, Kenneth H Buetow, Karen Taraszka Hastings

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  2. Article
  3. Article
  4. Review
  5. Interventions After First Post-Transplant Cutaneous Squamous Cell Carcinoma: A Proposed Decision Framework.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Elizabeth S BordenDepartment of Basic Medical Sciences, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, United States.
Paul KangDepartment of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Phoenix, AZ, United States.
Heini M NatriSchool of Life Sciences, Arizona State University, Tempe, AZ, United States.
Tanya N PhungSchool of Life Sciences, Arizona State University, Tempe, AZ, United States.
Melissa A WilsonSchool of Life Sciences, Arizona State University, Tempe, AZ, United States.
Kenneth H BuetowSchool of Life Sciences, Arizona State University, Tempe, AZ, United States.
Karen Taraszka HastingsDepartment of Basic Medical Sciences, College of Medicine Phoenix, University of Arizona, Phoenix, AZ, United States.
Arizona State University · USUniversity of Arizona · USUniversity of Phoenix · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A low percentage of actinic keratoses progress to develop into cutaneous squamous cell carcinoma. The immune mechanisms that successfully control or eliminate the majority of actinic keratoses and the mechanisms of immune escape by invasive squamous cell carcinoma are not well-understood. Here, we took a systematic approach to evaluate the neoantigens present in actinic keratosis and cutaneous squamous cell carcinoma specimens. We compared the number of mutations, the number of neoantigens predicted to bind MHC class I, and the number of neoantigens that are predicted to bind MHC class I and be recognized by a T cell receptor in actinic keratoses and cutaneous squamous cell carcinomas. We also considered the relative binding strengths to both MHC class I and the T cell receptor in a fitness cost model that allows for a comparison of the immune recognition potential of the neoantigens in actinic keratosis and cutaneous squamous cell carcinoma samples. The fitness cost was subsequently adjusted by the expression rates of the neoantigens to examine the role of neoantigen expression in tumor immune evasion. Our analyses indicate that, while the number of mutations and neoantigens are not significantly different between actinic keratoses and cutaneous squamous cell carcinomas, the predicted immune recognition of the neoantigen with the highest expression-adjusted fitness cost is lower for cutaneous squamous cell carcinomas compared with actinic keratoses. These findings suggest a role for the down-regulation of expression of highly immunogenic neoantigens in the immune escape of cutaneous squamous cell carcinomas. Furthermore, these findings highlight the importance of incorporating additional factors, such as the quality and expression of the neoantigens, rather than focusing solely on tumor mutational burden, in assessing immune recognition potential.

Indexed as

Biomarkers, TumorDisease SusceptibilityAlgorithmsAntigens, NeoplasmCarcinoma, Squamous CellEpitope MappingEpitopesExome SequencingHistocompatibility TestingHLA AntigensHumansKeratosis, ActinicLymphocytes, Tumor-InfiltratingModels, BiologicalMutationSkin NeoplasmsAntigens, NeoplasmBiomarkers, TumorEpitopesHLA Antigensactinic keratosiscancercutaneous squamous cell carcinomaimmunoeditingMHC class IneoantigenT cell receptor

Identifiers

PMID31849976
PMCPMC6896054
OpenAlexW2987408018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.